ArticleProtein science : a publication of the Protein Society2026
Cardiomyopathy-associated and basic residue mutations in myopalladin alter actin binding, bundling, and structural stability.
Article in Protein science : a publication of the Protein Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Myopalladin (MYPN) is a striated muscle-specific protein essential for sarcomere integrity and actin filament organization. The Ig3 domain of MYPN mediates direct binding and bundling of filamentous actin (F-actin), and several cardiomyopathy (CM)-associated mutations cluster within this domain. To elucidate the molecular basis of MYPN-actin interactions, we performed alanine-scanning mutagenesis of conserved basic residues and evaluated CM-linked variants of the Ig3 domain using co-sedimentation assays. These mutations impaired actin binding and abolished bundling activity, despite preserving secondary structure in most cases. Circular dichroism revealed that the P961L variant adopts a more open, partially unfolded β-sandwich conformation, distinct from the wild type (WT), which correlates with its aggregation and mislocalization in Drosophila cardiomyocytes. In vivo expression of full-length WT and mutant MYPN in Drosophila muscle confirmed Z-disc localization for WT, while R955W and P961L mutants formed aberrant clusters. Biochemical assays demonstrated that MYPN Ig3 promotes actin polymerization and bundling even under non-polymerizing conditions, and its interaction with actin is electrostatically driven but calcium-independent. Sedimentation equilibrium analysis confirmed that MYPN Ig3 functions as a monomer, suggesting that bundling arises from dual actin-binding surfaces rather than from self-oligomerization. These findings establish the Ig3 domain as a structurally robust, actin-regulatory module and identify disruption of MYPN-actin interactions as a pathogenic mechanism in CM. Our study provides the first direct evidence linking Ig3 domain mutations to impaired actin dynamics and sarcomere disorganization, offering mechanistic insight into MYPN-associated cardiomyopathies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.